샘플 요청 목록

 카트 문의
시장보고서
상품코드
1665882

연속 혈당 모니터링 시장 : 성장, 전망, 경쟁 분석(2025-2033년)

Continuous Glucose Monitoring Market - Growth, Future Prospects and Competitive Analysis, 2025 - 2033
발행일: | 리서치사: Acute Market Reports | 페이지 정보: 영문 180 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

연속 혈당 모니터링(CGM) 시스템은 밤낮을 가리지 않고 실시간으로 혈당 수치를 추적하는 첨단 의료기기입니다. CGM 시스템을 통해 당뇨병 환자는 자신의 혈당 수치를 실시간으로 확인할 수 있으며, 신체에 부착된 센서를 통해 며칠 동안 원격으로 모니터링할 수 있으며, 혈당 수치의 추세와 패턴을 파악하여 식단, 운동, 인슐린 요구량을 조정하는 데 사용할 수 있는 데이터를 제공합니다. 인슐린 필요량을 조절하는 데 도움이 됩니다. 이 기술은 한 번에 하나의 포도당 측정값만 제공하는 기존 혈당 측정기와 달리 포도당 동역학에 대한 종합적인 통찰력을 제공하기 때문에 당뇨병 관리에 필수적인 기술입니다. 연속 혈당 모니터링 시장 규모는 전 세계 당뇨병 유병률 증가와 실시간 혈당 모니터링 솔루션에 대한 수요 증가로 인해 연평균 9.6%의 성장률(CAGR)로 확대될 것으로 예상됩니다.

연속 혈당 모니터링(CGM) 시장의 중요한 촉진요인은 전 세계 당뇨병 유병률 증가입니다. 당뇨병은 전 세계적으로 유행하고 있으며, 2021년에는 5억 3,700만 명의 성인이 당뇨병을 앓고 있는 것으로 추정되며, 2030년에는 6억 4,300만 명으로 증가할 것으로 예상됩니다. 이러한 급격한 증가는 특히 도시 지역의 비만, 식생활의 변화, 앉아서 생활하는 생활습관 증가에 기인하는 바가 큽니다. 당뇨병 인구 증가로 인해 혈당 수치를 모니터링하고 관리할 수 있는 효과적인 관리 도구가 필요하며, CGM 시스템에 대한 수요가 증가하고 있습니다. 이러한 장치는 혈당 동향에 대한 실시간 통찰력을 제공하여 환자가 자신의 상태를 보다 효과적으로 관리하고 적시에 개입할 수 있도록 지원함으로써 저혈당 및 고혈당과 같은 당뇨병 관련 합병증의 위험을 줄일 수 있습니다.

CGM 시장의 성장 기회는 CGM 기기와 광범위한 디지털 건강 플랫폼과의 통합으로 크게 강화될 것입니다. 디지털 헬스 기술이 발전함에 따라 CGM 시스템을 포함한 여러 소스의 데이터를 통합하여 환자의 건강 상태를 종합적으로 파악할 수 있는 플랫폼의 개발 추세가 강화되고 있습니다. 이러한 통합은 식습관, 운동 및 기타 건강 데이터를 기반으로 포도당 변동을 예측할 수 있는 인공지능 및 머신러닝 알고리즘을 통해 보다 개인화되고 정확한 당뇨병 관리 전략을 가능하게 합니다. 또한, 이 데이터를 의료진과 원활하게 공유할 수 있어 원격 모니터링 기능이 강화되어 원격 의료 및 원격 건강 관리를 향한 전 세계적인 움직임 속에서 특히 중요한 원격지에서의 효과적인 당뇨병 관리를 용이하게 해줍니다.

세계의 연속 혈당 모니터링 시장에 대해 조사했으며, 시장 개요, 기기별/브랜드별/지역별 동향, 시장 진출기업 프로파일 등의 정보를 전해드립니다.

목차

제1장 서문

제2장 주요 요약

제3장 연속 혈당 모니터링 시장 : 경쟁 분석

  • 주요 벤더의 시장 포지셔닝
  • 벤더가 채택하는 전략
  • 주요 업계 전략

제4장 연속 혈당 모니터링 시장 : 매크로 분석과 시장 역학

  • 서론
  • 세계의 지속 혈당 모니터링 시장 가치, 2023년-2033년
  • 시장 역학
  • 성장 촉진요인과 억제요인의 영향 분석
  • See-Saw 분석
  • Porter's Five Forces 모델
  • PESTEL 분석

제5장 연속 혈당 모니터링 시장 : 2023년-2033년

  • 시장 개요
  • 성장과 매출 분석 : 2024년 vs. 2033년
  • 시장 세분화

제6장 연속 혈당 모니터링 시장 : 디바이스/브랜드별, 2023년-2033년

  • 시장 개요
  • 성장과 매출 분석 : 2024년 vs. 2033년
  • 시장 세분화
    • Guardian Real Time CGM System
    • Dexcom Seven Plus
    • Dexcom G4 Platinum
    • FreeStyle Navigator
    • MiniMed Paradigm Revel/Veo System
    • 기타

제7장 북미의 연속 혈당 모니터링 시장 : 2023년-2033년

제8장 영국 및 EU의 연속 혈당 모니터링 시장 : 2023년-2033년

제9장 아시아태평양의 연속 혈당 모니터링 시장 : 2023년-2033년

제10장 라틴아메리카의 연속 혈당 모니터링 시장 : 2023년-2033년

제11장 중동 및 아프리카의 연속 혈당 모니터링 시장 : 2023년-2033년

제12장 기업 개요

  • Abbott
  • Bayer AG
  • Dexcom Inc.
  • Glysens Incorporated
  • Insulet Corporation
  • Medtronic
  • Nova Biomedical Corporation
  • Senseonics Incorporated
  • Livongo
  • BeatO
  • Jana Care
  • iXensor
  • DiaMonTech AG.
LSH 25.03.12

Continuous Glucose Monitoring (CGM) systems are advanced medical devices that track glucose levels in real-time throughout the day and night. These systems allow individuals with diabetes to see their glucose levels in real-time or monitor them remotely over several days via sensors that are attached to the body. CGM systems provide data that can be used to identify trends and patterns in glucose levels, which can help in tailoring diet, exercise, and insulin requirements. This technology is vital for diabetes management as it provides comprehensive insights into glucose dynamics, unlike traditional blood glucose meters, which only provide a single glucose reading at a time. The continuous glucose monitoring market is projected to expand at a Compound Annual Growth Rate (CAGR) of 9.6%, driven by the increasing prevalence of diabetes globally and the growing demand for real-time glucose monitoring solutions.

Increasing Prevalence of Diabetes

A significant driver for the continuous glucose monitoring (CGM) market is the escalating prevalence of diabetes worldwide. Diabetes has become a global epidemic, with an estimated 537 million adults living with the condition in 2021, a number expected to rise to 643 million by 2030. This surge is largely due to increasing rates of obesity, poor dietary habits, and sedentary lifestyles, especially in urban environments. The growing diabetic population necessitates effective management tools to monitor and control blood glucose levels, thus driving demand for CGM systems. These devices provide real-time insights into glucose trends, enabling patients to manage their condition more effectively and reduce the risk of diabetes-related complications, such as hypoglycemia and hyperglycemia, by facilitating timely interventions.

Integration with Digital Health Platforms

The opportunity for growth in the CGM market is significantly enhanced by the integration of CGM devices with broader digital health platforms. As digital health technology advances, there is a growing trend toward the development of platforms that can integrate data from multiple sources, including CGM systems, to provide a comprehensive overview of a patient's health. This integration allows for more personalized and precise diabetes management strategies, supported by artificial intelligence and machine learning algorithms that can predict glucose fluctuations based on diet, exercise, and other health data. Moreover, the ability to share this data seamlessly with healthcare providers enhances remote monitoring capabilities, making it easier to manage diabetes effectively from a distance, particularly important in the context of the ongoing global push towards telemedicine and remote health management.

Cost and Accessibility Barriers

Despite the benefits of CGM systems, a significant restraint is their cost, which remains prohibitively high for many potential users, especially in low- and middle-income countries. The expense of CGM devices, which includes not only the initial purchase price but also ongoing costs related to sensors, which need regular replacement, can be a barrier to widespread adoption. Additionally, there are accessibility issues, as these systems often require a certain level of technological literacy and access to supportive digital infrastructure, such as smartphones or reliable internet, which may not be available to all users. This economic and technological divide limits the potential market reach of CGM systems and poses challenges to their universal adoption among the global diabetic population.

Data Privacy and Security Concerns

A critical challenge in the CGM market is addressing concerns related to data privacy and security. As CGM systems collect and store vast amounts of personal health information, there is an inherent risk of data breaches, which could expose sensitive health data. The challenge is compounded as these devices become more interconnected with other health systems and platforms, increasing the number of potential vulnerability points. Ensuring robust data protection measures is paramount to maintaining user trust and compliance with stringent regulatory standards regarding health data. This requires continuous investment in cybersecurity measures and regular updates to security protocols, which can be resource-intensive but are essential for safeguarding patient information and ensuring the integrity of remote monitoring health services.

Market Segmentation by Device/Brand

In the continuous glucose monitoring (CGM) market, segmentation by device/brand includes Guardian Real Time CGM System, Dexcom Seven Plus, Dexcom G4 Platinum, FreeStyle Navigator, MiniMed Paradigm Revel/Veo System, and others. Currently, the Dexcom G4 Platinum holds the highest revenue within this segment, attributed to its high accuracy, reliability, and user-friendly interface, which have made it popular among diabetes patients seeking rigorous glucose management. Dexcom's strong brand recognition and established distribution channels contribute significantly to its leading market position. However, the FreeStyle Navigator is projected to experience the highest CAGR. This anticipated growth is driven by its newer technology that offers real-time glucose monitoring without the need for fingerstick calibration, providing greater convenience and reducing the invasiveness of glucose monitoring. As technology advances and patient preferences evolve towards less invasive and more integrated diabetes management solutions, devices like the FreeStyle Navigator are expected to gain significant traction, reflecting broader trends in patient-centered healthcare innovations.

Geographic Trends in the Continuous Glucose Monitoring Market

The continuous glucose monitoring (CGM) market exhibits substantial geographic variations, with North America having generated the highest revenue in 2024. This region's market dominance is attributed to a high prevalence of diabetes, well-established healthcare infrastructure, and widespread adoption of advanced diabetes management technologies. Additionally, favorable reimbursement policies and strong presence of major market players have further supported the extensive use of CGM systems in this region. However, Asia-Pacific is expected to witness the highest CAGR from 2025 to 2033. This growth is driven by increasing awareness of diabetes management, rising healthcare expenditures, and improving healthcare infrastructures in populous countries like China and India. Moreover, the growing middle class in this region is increasingly able to afford advanced healthcare solutions, which contributes to the rapid adoption of innovative technologies such as CGM systems.

Competitive Trends and Key Strategies

In 2024, the competitive landscape of the CGM market was shaped by key players such as Abbott, Bayer AG, Dexcom, Inc., Glysens Incorporated, Insulet Corporation, Medtronic, Nova Biomedical Corporation, Senseonics Incorporated, Livongo, BeatO, Jana Care, iXensor, and DiaMonTech AG. These companies employed a range of strategies to enhance their market positions, including innovation in product offerings, strategic partnerships, and expansions into new geographic markets. For instance, companies like Dexcom and Medtronic focused on technological advancements to improve the accuracy and user-friendliness of their CGM systems, which helped solidify their leadership in the market. Abbott expanded its global footprint by launching its highly popular FreeStyle Libre system in additional international markets, thus broadening its customer base. From 2025 to 2033, these players are expected to continue their focus on innovation, particularly in integrating artificial intelligence to enhance predictive capabilities of CGM devices. Strategic alliances and mergers are anticipated to be prevalent as companies strive to expand their technological capabilities and access new markets. Moreover, as the competition intensifies, companies are likely to invest more in consumer education and direct-to-consumer marketing strategies to increase the adoption rates of their CGM products. The focus on developing less invasive, more accurate, and more integrated CGM solutions will drive the competitive dynamics in this fast-evolving market.

Historical & Forecast Period

This study report represents an analysis of each segment from 2023 to 2033 considering 2024 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2025 to 2033.

The current report comprises quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends & technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. The key data points that enable the estimation of Continuous Glucose Monitoring market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users & consumption volume, price, and value.

Geographical revenues generated by countries considered in the report

Micro and macro environment factors that are currently influencing the Continuous Glucose Monitoring market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top-down and bottom-up approach for validation of market estimation assures logical, methodical, and mathematical consistency of the quantitative data.

  • Market Segmentation
    • Device/Brand
  • Guardian Real Time CGM System
  • Dexcom Seven Plus
  • Dexcom G4 Platinum
  • FreeStyle Navigator
  • MiniMed Paradigm Revel/Veo System
  • Others
  • Region Segment (2023-2033; US$ Million)
  • North America
  • U.S.
  • Canada
  • Rest of North America
  • UK and European Union
  • UK
  • Germany
  • Spain
  • Italy
  • France
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East and Africa
  • GCC
  • Africa
  • Rest of Middle East and Africa

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Continuous Glucose Monitoring market?
  • What are the key investment pockets concerning product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2033.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Continuous Glucose Monitoring market?
  • Which is the largest regional market for Continuous Glucose Monitoring market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Continuous Glucose Monitoring market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Continuous Glucose Monitoring market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Continuous Glucose Monitoring Market
  • 2.2. Global Continuous Glucose Monitoring Market, By , 2024 (US$ Million)
  • 2.3. Global Continuous Glucose Monitoring Market, By Device/Brand, 2024 (US$ Million)
  • 2.4. Global Continuous Glucose Monitoring Market, By Geography, 2024 (US$ Million)
  • 2.5. Attractive Investment Proposition by Geography, 2024

3. Continuous Glucose Monitoring Market: Competitive Analysis

  • 3.1. Market Positioning of Key Continuous Glucose Monitoring Market Vendors
  • 3.2. Strategies Adopted by Continuous Glucose Monitoring Market Vendors
  • 3.3. Key Industry Strategies

4. Continuous Glucose Monitoring Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Continuous Glucose Monitoring Market Value, 2023 - 2033, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis
  • 4.6. Porter's Five Force Model
    • 4.6.1. Supplier Power
    • 4.6.2. Buyer Power
    • 4.6.3. Threat Of Substitutes
    • 4.6.4. Threat Of New Entrants
    • 4.6.5. Competitive Rivalry
  • 4.7. PESTEL Analysis
    • 4.7.1. Political Landscape
    • 4.7.2. Economic Landscape
    • 4.7.3. Technology Landscape
    • 4.7.4. Legal Landscape
    • 4.7.5. Social Landscape

5. Continuous Glucose Monitoring Market: By , 2023-2033, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2024 Versus 2033
  • 5.3. Market Segmentation

6. Continuous Glucose Monitoring Market: By Device/Brand, 2023-2033, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2024 Versus 2033
  • 6.3. Market Segmentation
    • 6.3.1. Guardian Real Time CGM System
    • 6.3.2. Dexcom Seven Plus
    • 6.3.3. Dexcom G4 Platinum
    • 6.3.4. FreeStyle Navigator
    • 6.3.5. MiniMed Paradigm Revel/Veo System
    • 6.3.6. Others

7. North America Continuous Glucose Monitoring Market, 2023-2033, USD (Million)

  • 7.1. Market Overview
  • 7.2. Continuous Glucose Monitoring Market: By , 2023-2033, USD (Million)
  • 7.3. Continuous Glucose Monitoring Market: By Device/Brand, 2023-2033, USD (Million)
  • 7.4.Continuous Glucose Monitoring Market: By Region, 2023-2033, USD (Million)
    • 7.4.1.North America
      • 7.4.1.1. U.S.
        • 7.4.1.1.1. Continuous Glucose Monitoring Market: By , 2023-2033, USD (Million)
        • 7.4.1.1.2. Continuous Glucose Monitoring Market: By Device/Brand, 2023-2033, USD (Million)
      • 7.4.1.2. Canada
        • 7.4.1.2.1. Continuous Glucose Monitoring Market: By , 2023-2033, USD (Million)
        • 7.4.1.2.2. Continuous Glucose Monitoring Market: By Device/Brand, 2023-2033, USD (Million)
      • 7.4.1.3. Rest of North America
        • 7.4.1.3.1. Continuous Glucose Monitoring Market: By , 2023-2033, USD (Million)
        • 7.4.1.3.2. Continuous Glucose Monitoring Market: By Device/Brand, 2023-2033, USD (Million)

8. UK and European Union Continuous Glucose Monitoring Market, 2023-2033, USD (Million)

  • 8.1. Market Overview
  • 8.2. Continuous Glucose Monitoring Market: By , 2023-2033, USD (Million)
  • 8.3. Continuous Glucose Monitoring Market: By Device/Brand, 2023-2033, USD (Million)
  • 8.4.Continuous Glucose Monitoring Market: By Region, 2023-2033, USD (Million)
    • 8.4.1.UK and European Union
      • 8.4.1.1. UK
        • 8.4.1.1.1. Continuous Glucose Monitoring Market: By , 2023-2033, USD (Million)
        • 8.4.1.1.2. Continuous Glucose Monitoring Market: By Device/Brand, 2023-2033, USD (Million)
      • 8.4.1.2. Germany
        • 8.4.1.2.1. Continuous Glucose Monitoring Market: By , 2023-2033, USD (Million)
        • 8.4.1.2.2. Continuous Glucose Monitoring Market: By Device/Brand, 2023-2033, USD (Million)
      • 8.4.1.3. Spain
        • 8.4.1.3.1. Continuous Glucose Monitoring Market: By , 2023-2033, USD (Million)
        • 8.4.1.3.2. Continuous Glucose Monitoring Market: By Device/Brand, 2023-2033, USD (Million)
      • 8.4.1.4. Italy
        • 8.4.1.4.1. Continuous Glucose Monitoring Market: By , 2023-2033, USD (Million)
        • 8.4.1.4.2. Continuous Glucose Monitoring Market: By Device/Brand, 2023-2033, USD (Million)
      • 8.4.1.5. France
        • 8.4.1.5.1. Continuous Glucose Monitoring Market: By , 2023-2033, USD (Million)
        • 8.4.1.5.2. Continuous Glucose Monitoring Market: By Device/Brand, 2023-2033, USD (Million)
      • 8.4.1.6. Rest of Europe
        • 8.4.1.6.1. Continuous Glucose Monitoring Market: By , 2023-2033, USD (Million)
        • 8.4.1.6.2. Continuous Glucose Monitoring Market: By Device/Brand, 2023-2033, USD (Million)

9. Asia Pacific Continuous Glucose Monitoring Market, 2023-2033, USD (Million)

  • 9.1. Market Overview
  • 9.2. Continuous Glucose Monitoring Market: By , 2023-2033, USD (Million)
  • 9.3. Continuous Glucose Monitoring Market: By Device/Brand, 2023-2033, USD (Million)
  • 9.4.Continuous Glucose Monitoring Market: By Region, 2023-2033, USD (Million)
    • 9.4.1.Asia Pacific
      • 9.4.1.1. China
        • 9.4.1.1.1. Continuous Glucose Monitoring Market: By , 2023-2033, USD (Million)
        • 9.4.1.1.2. Continuous Glucose Monitoring Market: By Device/Brand, 2023-2033, USD (Million)
      • 9.4.1.2. Japan
        • 9.4.1.2.1. Continuous Glucose Monitoring Market: By , 2023-2033, USD (Million)
        • 9.4.1.2.2. Continuous Glucose Monitoring Market: By Device/Brand, 2023-2033, USD (Million)
      • 9.4.1.3. India
        • 9.4.1.3.1. Continuous Glucose Monitoring Market: By , 2023-2033, USD (Million)
        • 9.4.1.3.2. Continuous Glucose Monitoring Market: By Device/Brand, 2023-2033, USD (Million)
      • 9.4.1.4. Australia
        • 9.4.1.4.1. Continuous Glucose Monitoring Market: By , 2023-2033, USD (Million)
        • 9.4.1.4.2. Continuous Glucose Monitoring Market: By Device/Brand, 2023-2033, USD (Million)
      • 9.4.1.5. South Korea
        • 9.4.1.5.1. Continuous Glucose Monitoring Market: By , 2023-2033, USD (Million)
        • 9.4.1.5.2. Continuous Glucose Monitoring Market: By Device/Brand, 2023-2033, USD (Million)
      • 9.4.1.6. Rest of Asia Pacific
        • 9.4.1.6.1. Continuous Glucose Monitoring Market: By , 2023-2033, USD (Million)
        • 9.4.1.6.2. Continuous Glucose Monitoring Market: By Device/Brand, 2023-2033, USD (Million)

10. Latin America Continuous Glucose Monitoring Market, 2023-2033, USD (Million)

  • 10.1. Market Overview
  • 10.2. Continuous Glucose Monitoring Market: By , 2023-2033, USD (Million)
  • 10.3. Continuous Glucose Monitoring Market: By Device/Brand, 2023-2033, USD (Million)
  • 10.4.Continuous Glucose Monitoring Market: By Region, 2023-2033, USD (Million)
    • 10.4.1.Latin America
      • 10.4.1.1. Brazil
        • 10.4.1.1.1. Continuous Glucose Monitoring Market: By , 2023-2033, USD (Million)
        • 10.4.1.1.2. Continuous Glucose Monitoring Market: By Device/Brand, 2023-2033, USD (Million)
      • 10.4.1.2. Mexico
        • 10.4.1.2.1. Continuous Glucose Monitoring Market: By , 2023-2033, USD (Million)
        • 10.4.1.2.2. Continuous Glucose Monitoring Market: By Device/Brand, 2023-2033, USD (Million)
      • 10.4.1.3. Rest of Latin America
        • 10.4.1.3.1. Continuous Glucose Monitoring Market: By , 2023-2033, USD (Million)
        • 10.4.1.3.2. Continuous Glucose Monitoring Market: By Device/Brand, 2023-2033, USD (Million)

11. Middle East and Africa Continuous Glucose Monitoring Market, 2023-2033, USD (Million)

  • 11.1. Market Overview
  • 11.2. Continuous Glucose Monitoring Market: By , 2023-2033, USD (Million)
  • 11.3. Continuous Glucose Monitoring Market: By Device/Brand, 2023-2033, USD (Million)
  • 11.4.Continuous Glucose Monitoring Market: By Region, 2023-2033, USD (Million)
    • 11.4.1.Middle East and Africa
      • 11.4.1.1. GCC
        • 11.4.1.1.1. Continuous Glucose Monitoring Market: By , 2023-2033, USD (Million)
        • 11.4.1.1.2. Continuous Glucose Monitoring Market: By Device/Brand, 2023-2033, USD (Million)
      • 11.4.1.2. Africa
        • 11.4.1.2.1. Continuous Glucose Monitoring Market: By , 2023-2033, USD (Million)
        • 11.4.1.2.2. Continuous Glucose Monitoring Market: By Device/Brand, 2023-2033, USD (Million)
      • 11.4.1.3. Rest of Middle East and Africa
        • 11.4.1.3.1. Continuous Glucose Monitoring Market: By , 2023-2033, USD (Million)
        • 11.4.1.3.2. Continuous Glucose Monitoring Market: By Device/Brand, 2023-2033, USD (Million)

12. Company Profile

  • 12.1. Abbott
    • 12.1.1. Company Overview
    • 12.1.2. Financial Performance
    • 12.1.3. Product Portfolio
    • 12.1.4. Strategic Initiatives
  • 12.2. Bayer AG
    • 12.2.1. Company Overview
    • 12.2.2. Financial Performance
    • 12.2.3. Product Portfolio
    • 12.2.4. Strategic Initiatives
  • 12.3. Dexcom, Inc.
    • 12.3.1. Company Overview
    • 12.3.2. Financial Performance
    • 12.3.3. Product Portfolio
    • 12.3.4. Strategic Initiatives
  • 12.4. Glysens Incorporated
    • 12.4.1. Company Overview
    • 12.4.2. Financial Performance
    • 12.4.3. Product Portfolio
    • 12.4.4. Strategic Initiatives
  • 12.5. Insulet Corporation
    • 12.5.1. Company Overview
    • 12.5.2. Financial Performance
    • 12.5.3. Product Portfolio
    • 12.5.4. Strategic Initiatives
  • 12.6. Medtronic
    • 12.6.1. Company Overview
    • 12.6.2. Financial Performance
    • 12.6.3. Product Portfolio
    • 12.6.4. Strategic Initiatives
  • 12.7. Nova Biomedical Corporation
    • 12.7.1. Company Overview
    • 12.7.2. Financial Performance
    • 12.7.3. Product Portfolio
    • 12.7.4. Strategic Initiatives
  • 12.8. Senseonics Incorporated
    • 12.8.1. Company Overview
    • 12.8.2. Financial Performance
    • 12.8.3. Product Portfolio
    • 12.8.4. Strategic Initiatives
  • 12.9. Livongo
    • 12.9.1. Company Overview
    • 12.9.2. Financial Performance
    • 12.9.3. Product Portfolio
    • 12.9.4. Strategic Initiatives
  • 12.10. BeatO
    • 12.10.1. Company Overview
    • 12.10.2. Financial Performance
    • 12.10.3. Product Portfolio
    • 12.10.4. Strategic Initiatives
  • 12.11. Jana Care
    • 12.11.1. Company Overview
    • 12.11.2. Financial Performance
    • 12.11.3. Product Portfolio
    • 12.11.4. Strategic Initiatives
  • 12.12. iXensor
    • 12.12.1. Company Overview
    • 12.12.2. Financial Performance
    • 12.12.3. Product Portfolio
    • 12.12.4. Strategic Initiatives
  • 12.13. DiaMonTech AG.
    • 12.13.1. Company Overview
    • 12.13.2. Financial Performance
    • 12.13.3. Product Portfolio
    • 12.13.4. Strategic Initiatives
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제